PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

vigabatrin Side Effects

The reactions most often reported to the FDA for vigabatrin (also sold as Sabril), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

14,085
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2004 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of vigabatrin come from 14,085 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 14,085 reports to the FDA Adverse Event Reporting System (FAERS) for vigabatrin (Sabril): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

14,085

Reports Mentioning Death

1,350

9.6% of reports — not proof the medicine caused the death

Hospitalizations

4,439

31.5% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

SEIZURE
2,570
DRUG DOSE OMISSION
990
DEATH
855
SOMNOLENCE
553
PNEUMONIA
523
DRUG WITHDRAWAL CONVULSIONS
465
VOMITING
457
HOSPITALISATION
312
INFANTILE SPASMS
297
EPILEPSY
296
CONDITION AGGRAVATED
281
IRRITABILITY
273
CONVULSION
267
PYREXIA
267
STATUS EPILEPTICUS
252
ADVERSE EVENT
251
INSOMNIA
232

Who Reports Side Effects

Gender Distribution

Female 6,034 (49%)
Male 6,377 (51%)
Unknown 19

Age Distribution

0-17 6,034 (77%)
18-44 1,410 (18%)
45-64 344 (4%)
65-74 54 (1%)
75+ 29 (0%)

Reporting Trend by Year

2004 2025

Reactions in Death Reports

Top reactions reported in 1,350 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
DEATH 852
RESPIRATORY FAILURE 81
ADVERSE EVENT 74
SEIZURE 50
PNEUMONIA 47
CARDIAC ARREST 40
STATUS EPILEPTICUS 30
SUDDEN UNEXPLAINED DEATH IN EPILEPSY 26
RESPIRATORY DISTRESS 24
CARDIO-RESPIRATORY ARREST 20
ACUTE RESPIRATORY FAILURE 19
CONVULSION 18
EPILEPSY 18
RESPIRATORY ARREST 14
TOXICITY TO VARIOUS AGENTS 14
MULTIPLE-DRUG RESISTANCE 13
PYREXIA 13
RESPIRATORY DISORDER 13

Reactions in Hospitalization Reports

Top reactions in 4,439 reports where hospitalization was an outcome.

Reaction Reports
SEIZURE 1,114
PNEUMONIA 433
HOSPITALISATION 303
VOMITING 184
STATUS EPILEPTICUS 176
SOMNOLENCE 175
PYREXIA 167
ADVERSE EVENT 155
EPILEPSY 137
CONVULSION 131
CONDITION AGGRAVATED 125
RESPIRATORY DISTRESS 119
INFANTILE SPASMS 116
PNEUMONIA ASPIRATION 110
RESPIRATORY DISORDER 109
DRUG WITHDRAWAL CONVULSIONS 107
URINARY TRACT INFECTION 104

Compare vigabatrin vs brivaracetam →

What the FAERS Data Reveals About vigabatrin Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 14,085 voluntary reports linked to vigabatrin and its brand equivalents (Sabril), spanning 2004 through 2025. Of those, 1,350 (9.6%) listed death as an outcome and 4,439 (31.5%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 49% were female and 51% male; age distribution skews toward 0-17, with 6,034 reports in that bracket. The single most reported reaction is seizure with 2,570 submissions, followed by drug dose omission and death.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.